Wells Fargo raised its price target on Ascendis Pharma to $330 from $326 while keeping an Overweight rating on the stock. The firm made the adjustment following the company's third-quarter results.
Wells Fargo cited underappreciated operating leverage and expects Street estimates to rise as margins scale. Ascendis posted a gross profit margin of 92% over the last twelve months.
Ascendis expects Yorvipath to sustain growth with approximately 1,000 new patient additions per quarter, 300 new prescribers in the third quarter, and rising script depth in the U.S. market.
The company plans to expand Yorvipath from more than 40 countries through 2026 into 15 additional countries in 2027. Management targets approximately €5 billion in 2030 revenue.
Wells Fargo believes Street estimates of approximately $1.6 billion in fiscal year 2027 sales look achievable or beatable versus the firm's approximately $1.9 billion estimate. Ascendis delivered 86% revenue growth over the last twelve months.
In third-quarter earnings, Ascendis reported adjusted earnings of $1.08 per share, topping analyst estimates of 80 cents per share. Revenue reached $369.66 million, slightly above the anticipated $362.98 million.
Investors tracking ASND should monitor whether the company achieves management's 2027 sales guidance and maintains quarterly patient addition rates near 1,000 across its rare-disease portfolio.